RE: Another Q then17 Dec 2025 07:59
It is, or rather was, showing improved progression-free survival (PFS) over what is currently possible in the clinic, so that is a benefit. Phase 1b hasn't finished yet, so today's data release is not the final word.
You have to look at the broader picture though - pre|CISION works (concentrated targetting of cytotoxins, fewer side effects) and there are more powerful cytotoxins in the pipeline (exatecan, MMAE).